Dexamethasone reduces angiopoietin-2 (Ang-2), intercellular adhesion molecule 1 (ICAM-1), glycocalyx shedding and the soluble receptor for advanced glycation end-products (sRAGE) in critically ill COVID-19 patients, suggesting potential reduction in endothelial damage. Here, ANGPT2 is linked to COVID-19.